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miR-362-5p is down-regulated in high-risk neuroblastoma and can function as a tumor suppressor.
However, its role remains poorly understood. We show that miR-362-5p is down-regulated in meta-
static neuroblastoma compared with primary neuroblastoma. Overexpression of miR-362-5p inhi-
bits cell proliferation, migration and invasion of neuroblastoma cells in vitro and suppresses
tumor growth of neuroblastoma in vivo. Phosphatidylinositol 3-kinase (PI3K)-C2b is a target of
miR-362-5p. Knockdown of PI3K-C2b by siRNA had a similar effect to overexpression of
miR-362-5p on SH-SY5Y cells. Overexpression of PI3K-C2b partially reversed tumor-suppressive
effects of miR-362-5p. We suggest that miR-362-5p suppresses neuroblastoma cell growth and
motility, partially by targeting PI3K-C2b.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Neuroblastoma is one of the most common solid tumors in
childhood, and accounts for 7% of childhood malignancies and
about 15% of all childhood cancer deaths [1]. Although recent
multimodal treatments, such as surgery, chemoradiotherapy, stem
cell transplantation, and immunotherapy, have improved the
survival rate of neuroblastoma in the post 10 years [2], the overall
5-year survival rate of high-risk neuroblastoma is still very low and
its treatment remains challenging. Elucidating the molecular
mechanism will help in identifying new treatments for
neuroblastoma.
MicroRNAs (miRNAs) are endogenous small 22–25 nucleotide
non-coding RNAs. miRNA can bind to the 30-untranslated region
(30-UTR) of target mRNA and lead to translational repression ordegradation of mRNA. Single miRNA can regulate multiple
mRNAs and single mRNA can combine with multiple miRNAs.
Numerous studies suggest that miRNAs play an important role in
regulating various biological and pathologic processes, such as cell
proliferation, apoptosis, metastasis and differentiation [3,4].
Moreover, the development and progression of tumors are also
associated with abnormal expression of speciﬁc miRNAs [5,6].
miRNAs might serve as a new therapeutic strategy for cancer,
including neuroblastoma, by targeting oncogenes or serving as
tumor suppressors.
Many miRNAs were identiﬁed as down-regulated miRNAs in
high-risk neuroblastoma, and loss of their expression was associ-
ated with unfavorable prognosis [7]. Many misexpressed
miRNAs, such as miR-432, miR-124, miR-329, have been reported
to play an important role in tumor development and progression
[8–10]. miR-362-5p was identiﬁed by Bentwich et al. and played
an important role in tumor growth and metastasis [11].
Bienertova-Vasku et al. discovered that miR-362-5p expression
levels were signiﬁcantly down-regulated in metastatic neuroblas-
toma tissues compared with primary neuroblastoma tissues [7].
It has also been demonstrated that miR-362-5p plays an important
role in tumor cell proliferation, apoptosis, and metastasis [12–14].
In this study, we conﬁrmed that miR-362-5p is down-regulated
in metastatic neuroblastoma tissues compared with primary neu-
roblastoma tissues. In addition, we have identiﬁed the important
molecular mechanism by which miR-362-5p exerts its
tumor-suppressive effects on neuroblastoma cell proliferation,
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30-UTR of phosphatidylinositol 3-kinase (PI3K)-C2b mRNA.
2. Materials and methods
2.1. Tissue samples
After receiving approval from the institutional review board of
Zhujiang Hospital of Southern Medical University, 12 metastatic
and 12 primary neuroblastoma tissues were obtained from our
department. All the patients underwent Computed Tomography,
Magnetic Resonance Imaging, Bone Marrow Examination and care-
ful physical examination to distinguish whether the tumor metas-
tasis had occured. The diagnosis of these tissue samples was
veriﬁed pathologically and immunohistochemically. Pathologic
and clinic data, including tumor grade, invasion, and metastasis,
were collected. All the tissue samples were either immediately
snap-frozen in liquid nitrogen or stored at 80 C.
2.2. Cell culture and transfection
Human neuroblastoma cell lines SH-SY5Y and IMR-32 and
human embryonic kidney cell line HEK-293 were obtained from
the animal experimental center of Sun Yet-sen University
(Guangzhou, China). Cells were cultivated in DMEM with 10% FBS
(Gibco, NY, USA). All cells were maintained at 37 C in a humidiﬁed
atmosphere containing 5% CO2. The SH-SY5Y cell line was a sub-
clone of the parental SK-N-SH cell line. The primary site was thorax
and the metastatic site was bone marrow. And IMR-32 cells were
primary neuroblastoma cells which primary site was abdominal
and had 1p alternation [15].
Mature miR-362-5p mimics (20 nucleotide), miR-362-5p inhi-
bitors and negative control which was tested to be non-functional
gene were purchased from Shanghai GenePharma (Shanghai,
China). Transfection of miRNA mimics and inhibitors was per-
formed using Lipofectamine-2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions.
2.3. RNA preparation and quantitative real time (qRT)-PCR
RNA was extracted from cells or tissue samples using a mirVana
miRNA isolation kit (Ambion, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Small RNA fractions were separated
and puriﬁed. cDNA was obtained using M-MLV (Promega,
Madison, WI, USA). The PCR reaction conditions were: denaturing
the DNA at 94 C for 5 min, followed by 40 cycles of ampliﬁcation:
94 C for 60 s, 60 C for 60 s, 72 C for 60 s for data collection. The
relative expression level of miR-362-5p was detected using SYBR
Premix Ex Taq™Kits (TaKaRa, Tokyo, Japan) on an ABI 7500 ther-
mocycler (AppliedBiosystems, FosterCity, CA, USA), with U6 small
nuclear RNA (Applied Biosystems) as an endogenous control.
Primers were purchased from Beijing Genomics institution
(Beijing, China). The primers were as follows: miR-362-5p RT pri-
mers 50-GTCGTATCC AGTGCAGGGTCCGAGGTATTCGCACTGGATAC
GACACTCAC-30; PCR primers: forward 50-GTCACGAAATCCTTGGAA
CCTAG-30, reverse 50-TATGGTTGTTCTCGTCTCCTTCTC-30.
2.4. Plasmids
The small interfering RNA (siRNA) plasmid targeting PI3K-C2b
and PI3K-C2b expression plasmids was obtained from
GenePharma (Shanghai, China). The siRNA sequences for targeting
PI3K-C2b were 50-CTCAAGAGCTCTGGCCGAATC-30 (siRNA-1), 50-A
TGCTGAGACCCTGCGTAAGA-30 (siRNA-2). Scrambled sequences
from GenePharma which was conﬁrmed not to interact with any
mRNA sequence else was used as a negative control.2.5. Cell proliferation assays
Cell proliferation was measured using a cell counting kit
(CCK-8) (Beyotime Institute of Biotechnology, Jiangsu, China).
Cells were seeded in 96-well plates (4  103 cells per well) and cul-
tured for 48 h. The viability of SH-SY5Y cells transfected with
miR-362-5p mimics or negative control mimics was detected every
24 h after transfection. 10 ll CCK-8 was added to each well of the
96-well plates and incubated for 4 h. The optical density was
detected at 490 nm using a Bio-Rad 2550 EIA Reader (Bio-Rad,
Hercules, CA, USA).
2.6. Flow cytometry analysis
To determine the effect of miR-362-5p mimics on apoptosis of
SH-SY5Y cells, AnnexinV-ﬂuorescein isothiocyanate (FITC) and
propidium iodide (PI) (BD Biosciences, Franklin Lakes, NJ, USA)
were used for ﬂow cytometry analysis. Cells were treated with
miR-362-5p mimics and negative control for 24 h. The cells were
then harvested, washed twice with PBS, and adjusted to a concen-
tration of 5  105 cells/mL with PBS. Suspensions (200 ll) were
added to each labeled tube, 5 ll of Annexin V-FITC and 10 ll pro-
pidium iodide were added and the tubes were incubated for at
least 10 min at room temperature in the dark. Cells were assayed
by ﬂow cytometry (BD Biosciences, USA).
2.7. Tumor cell xenograft
A genomic sequence encoding miRNA-362-5p and negative
control were ampliﬁed and then cloned into pLenti6.3/V5-DEST
Gateway Vector (Invitrogen, USA). After conﬁrmed by gene
sequencing, the lentiviruses infected to SH-SY5Y cells.
All experimental procedures involving animals were approved
by the Animal Care and Use Committee of Southern Medical
University, China. 20 male nude mice (4–6 weeks old, 18–20 g)
were purchased from the Laboratory Animal Center of Sun
Yet-Sen University (Guangdong, China). SH-SY5Y cell suspensions
(either stably transfected with miR-362-5p or negative control)
were injected subcutaneously (5  106 cells in 200 ll). Mice were
observed daily to ensure that the injection sites were healthy.
Animals were sacriﬁced 20 days after injection, the relative expres-
sion of miR-362-5p was detected using qRT-PCR, and the ﬁnal
tumor volumes were determined. The tumor volume was calcu-
lated using the formula: tumor volume = 1/2 (length width2).
2.8. Cell migration and invasion assays
Cell migration and invasion assays were carried out using a BD
BioCoat™ Growth Factor Reduced Matrigel™ Invasion Chamber
according to the manufacturer’s instructions (BD Biosciences, San
Jose, CA, USA). First, cells were harvested and resuspended in
serum-free medium after pretreatment for 24 h with miR-362-5p
or negative control. Then, cells were seeded in the upper compart-
ments of an 8-lm Boyden chamber. Migration and invasion assays
were carried out with coated Matrigel (invasion) or uncoated
Matrigel (migration). After incubation for 24 h, cells migrated
and invaded through the lower chamber were ﬁxed with methanol,
stained with 0.5% crystal violet, and counted using a microscope.
2.9. Fluorescent reporter assays
Human PI3K-C2b 30-UTR harboring miR-362-5p potential
target-binding sequences and mutated PI3K-C2b 30-UTR, which
was not paired with miR-362-5p, was synthesized by
GenePharma (Shanghai, China). Luciferase vectors were made
between the Hind III and MluI sites. The luciferase activity was
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(Promega, Beijing, China). Luciferase activities were expressed as
the ratio between ﬁreﬂy luciferase and Renilla luciferase activities.
2.10. Western blot
Treated cells were washed twice with ice-cold PBS. Total pro-
teins from cells were lyzed with RIPA buffer. Equal amounts of pro-
tein were separated using 10% SDS–PAGE and transferred to
polyvinylidene ﬂuoride membranes. Following transfer, the mem-
branes were blocked for 1 h at room temperature and blotted with
an appropriate primary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and b-actin (Beyotime Institute of Biotechnology,
Jiangsu, China) overnight at 4 C. Horseradish-peroxidase-labeled
secondary antibodies (1:1500) were added and incubated
for 1 h at room temperature. Blots were visualized using ECL
detection reagents (Amersham Biosciences, Uppsala, Sweden).
b-Actin (Beyotime Institute of Biotechnology, Jiangsu, China)
served as a loading control. Bands were quantiﬁed using Image J
Software.
2.11. Statistical analysis
All data are expressed as mean ± standard deviation. The differ-
ences between groups were analyzed using Student’s t test when
only two groups were present, or assessed by one-way analysis
of variance (ANOVA) when more than two groups were compared.
All data were analyzed using SPSS (version 13.0; SPSS Inc., Chicago,
IL, USA) and Graph Pad Prism 5.0. In this study, P < 0.05 is
considered statistically signiﬁcant.Fig. 1. Expression level of miR-362-5p in neuroblastoma tissues and cells. NB, neuroblas
neuroblastoma tissues and primary neuroblastoma tissues. The expression of miR-362
expression was detected by qRT-PCR in different neuroblastoma cells. The relative expr3. Results
3.1. Association of miR-362-5p expression levels with neuroblastoma
risk factor
To investigate potential involvement of the miR-362-5p in the
process of human neuroblastoma metastasis, 12 human primary
and 12 metastatic neuroblastoma tissues was included in this
study. The clinic pathological features of neuroblastoma patients
were shown in Supplementary Table S1. The miR-362-5p expres-
sion was investigated by qRT-PCR. As shown in Fig. 1A, we found
that miR-362-5p was down-regulated in metastatic neuroblastoma
tissues compared with primary neuroblastoma tissues (P < 0.01).
Lower miR-362-5p expression was also highly associated with
patients who were diagnosed >1.5 years (1.54-fold; P < 0.05)
(Fig. 1B). Comparedwith stage 1, 2, 3 or 4s neuroblastoma, the stage
4 neuroblastoma tissues had lower miR-362-5p expression
(P < 0.01) (Fig. 1C). As shown in Fig. 1D, the miR-362-5p expression
in the metastatic neuroblastoma SH-SY5Y cell line was lower than
that in the primary neuroblastoma IMR-32 cells.
3.2. miR-362-5p inhibits proliferation and promotes apoptosis of SH-
SY5Y and IMR-32 cells in vitro
To investigate the effect of miR-362-5p on neuroblastoma cell
growth, SH-SY5Y and IMR-32 cells were transfected with
miR-362-5p mimics, miR-362-5p inhibitors or negative control.
The transfection efﬁciency was conﬁrmed by qRT-PCR. In both cell
lines, we found that the miR-362-5p expression in the miR-362-5p
mimics group was higher than that in the negative control grouptoma. (A) miR-362-5p expression was determined by qRT-PCR in human metastatic
-5p in (B) different diagnosis ages; (C) different stages of tumor. (D) miR-362-5p
ession of miR-362-5p was normalized to U6. **P < 0.01, *P < 0.05.
Fig. 2. Overexpression of miR-362-5p inhibits proliferation and promotes apoptosis of SH-SY5Y and IMR-32 cells in vitro. OD, optical density. (A) SH-SY5Y and (B) IMR-32
cells were transfected with miR-362-5p mimics, miR-362-5p inhibitors or negative control. The expression level of miR-362-5p was detected by qRT-PCR. Cell Counting Kit
(CCK-8) assay was performed to investigate the effect of miR-362-5p on the proliferation of SH-SY5Y (C) and IMR-32 cells (D) at different time points. (E) The effect of miR-
362-5p mimics on apoptosis of SH-SY5Y was detected by ﬂow cytometry analysis. *P < 0.05, **P < 0.01 compared with NC.
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expression (Fig. 2B). The CCK-8 assay showed that miR-362-5p
mimics signiﬁcantly inhibited the proliferation of SH-SY5Y cell
lines, while miR-362-5p inhibitors increased the cell viability
(Fig. 2C). miR-362-5p had similar effect on IMR-32 cells viability
(Fig. 2D). Moreover, ﬂow cytometry revealed that the proportion
of apoptotic and necrotic cells in the miR-362-5p mimic group
was signiﬁcant larger than the negative control group (P < 0.05)
(Fig. 2E). In other words, the miR-362-5p promoted apoptosis of
SH-SY5Y cells in vitro.
3.3. miR-362-5p inhibits tumor growth of neuroblastoma in vivo
Because our in vitro studies indicated that miR-362-5p proba-
bly acts as a tumor suppressor in neuroblastoma cells, we investi-
gated whether miR-362-5p could inhibit tumor growth of
neuroblastoma in vivo. At 20 days after injection, the relative
expression of miR-362-5p was detected by qRT-PCR. The expres-
sion level of miR-362-5p in tumors stably transfected with
miR-362-5p is signiﬁcantly higher than negative control
(P < 0.01) (Fig. 3A). As shown in Fig. 3B, tumor cells transfected
with miR-362-5p mimics formed smaller tumors than did the cells
transfected with the negative control. The tumors weresigniﬁcantly smaller in the miR-362-5p transfected group than in
the negative control transfected group (P < 0.01) (Fig. 3C).
3.4. miR-362-5p inhibits the migratory and invasive behavior of SH-
SY5Y and IMR-32 cells
As our results indicated, the expression of miR-362-5p in meta-
static tumor tissues is signiﬁcant lower than in primary neuroblas-
toma tissue. miR-362-5p may play a role in regulating
neuroblastoma metastasis. Therefore, in vitro invasion and migra-
tion assays were conducted. We found that miR-362-5p mimics
reduced the migration and invasion abilities of SH-SY5Y and
IMR-32 cells compared with negative control, while miR-362-5p
inhibitors had the opposite effect in both SH-SY5Y and IMR-32
cells (Fig. 4).
3.5. PI3K-C2b is target of miR-362-5p in neuroblastoma cells
To screen the function target of miR-362-5p in neuroblastoma
cells, Bioinformatics software TargetScan 6.2 (http://www.tar-
getscan.org/) was used to screen the target gene of miR-362-5p.
Considering the potential roles of candidate genes in neuroblas-
toma, PI3K-C2b, which plays an important role in signaling
Fig. 3. miR-362-5p reduces tumor growth of neuroblastoma in vivo. (A) The expression level of miR-362-5p in xenograft tumors was detected by qRT-PCR. SH-SY5Y cells
stably infected with miR-362-5p or negative control were injected subcutaneously into nude mice. (B) Representative images of xenograft tumors. (C) Tumor volumes formed
by miR-362-5p or negative control infected SH-SY5Y cell lines were measured at the end of the experiment (20 days after injection). **P < 0.01 compared with NC.
Fig. 4. Effect of miR-362-5p on SH-SY5Y and IMR-32 cells motility. Transwell assay was used to evaluate migration and invasion of SH-SY5Y cells transfected with miR-362-
5p mimics, miR-362-5p inhibitors and negative control mimics. (A) Migration; (B) invasion. (C and D) The graph represented the number of migratory or invasive IMR-32 cells
per ﬁeld. **P < 0.05 compared with NC.
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cell survival, cell migration, and intracellular protein trafﬁcking,
was selected as our candidate target. Inspection of the 30-UTR of
PI3K-C2b revealed only one potential miR-362-5p target site that
was closely positioned (Fig. 5A).A luciferase activity assay was used to determine the potential
interaction between miR-362-5p and PI3K-C2b. It was found that
miR-362-5p signiﬁcantly suppressed activity of wild-type 30-UTR
but not the mutant 30-UTR of PI3K-C2b in SH-SY5Y cells (Fig. 5B).
In addition, Western blot analysis showed that miR-362-5p mimics
Fig. 5. PI3K-C2b is a target of miR-362-5p in SH-SY5Y cells. (A) A schematic illustration of predicted seed region in the wild type (WT) PI3K-C2b 30-UTR as well as mutated
(Mut) 30-UTR used in this study. (B) Fluorescent reporter assays in SH-SY5Y cells. Cells were transfected with wild-type or mutant 30-UTR-reporter constructs together with
miR-362-5p or negative control. (C) Protein level of PI3K-C2b was detected by Western blot in SH-SY5Y cells transfected with miR-362-5p mimics, miR-362-5p inhibitors or
negative control. b-Actin was served as a loading control. (D) Intensity of PI3K-C2b protein compared to b-actin (n = 5). *P < 0.05, **P < 0.01 compared with NC. (E) Pearson’s
correlation analysis was carried out to evaluate the relationship between PI3K-C2b and miR-362-5p. The miR-362-5p expression were detected by qRT-PCR and normalized
to U6. (F and G) Protein level of PI3K-C2b in different neuroblastoma cells was tested by Western blot (n = 5). The PI3K-C2b protein levels were evaluated by Western blot and
normalized to b-actin.
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negative control (Fig. 5C and D).
Since PI3K-C2b was one of the targets of miR-362-5p in vitro,
we next evaluated the association between miR-362-5p and
PI3K-C2b from neuroblastoma tissues and cells. Western blot
found a signiﬁcantly reverse correlation between miR-362-5p
and PI3K-C2b in the neuroblastoma tissues (Fig. 5E, Pearson’s cor-
relation coefﬁcient = 0.747; P = 0.0000). The results showed that
the miR-362-5p expression and PI3K-C2b expression were comple-
mentary clinically and suggested that miR-362-5p might nega-
tively regulate the expression of PI3K-C2b in vivo. To further
investigate the relationship between the miR-362-5p expression
and PI3K-C2b expression, the PI3K-C2b protein levels of the pri-
mary and metastatic neuroblastoma cell lines were detected by
Western blot. As shown in Fig. 5F and G, the PI3K-C2b expression
in the metastatic neuroblastoma SH-SY5Y cells was signiﬁcant
higher than that in the primary neuroblastoma IMR-32 cells
(P < 0.05), while the miR-362-5p expression in the SH-SY5Y cells
were lower than that in the IMR-32 cells.
3.6. Inhibition of PI3K-C2b shows similar effects to miR-362-5p
overexpression
To study the effect of PI3K-C2b on neuroblastoma cell growth,
SH-SY5Y cells were transfected with PI3K-C2b siRNA or negative
control siRNA. Western blot results showed that both PI3K-C2bsiRNA (number 1 or number 2) decreased the protein level of
PI3K-C2b compared with negative control siRNA (P < 0.05)
(Fig. 6A and B). However, PI3K-C2b-siRNA-2 has a stronger inhibi-
tory effect than PI3K-C2b-siRNA-1 (P < 0.05). PI3K-C2b-siRNA-2
signiﬁcantly suppressed the growth, migration and invasion of
SH-SY5Y cells and showed a similar effect to miR-362-5p overex-
pression (Fig. 6C–E).
3.7. PI3K-C2b overexpression attenuates the suppressive effect of miR-
362-5p
Finally, we investigated whether overexpression of PI3K-C2b
could reverse the effect of miR-362-5p. The overexpression vector
pcDNA3/PI3K-C2b (without PI3K-C2b 30-UTR) tagged by GFP was
synthesized by GenePharma (Shanghai, China) and the empty
vector (pcDNA3) was served as negative control. First, the
transfection efﬁciency was determined by ﬂuorescence
microscopy and the effect of PI3K-C2b overexpression plasmid on
SH-SY5Y cells was conﬁrmed by Western blot. As shown in
Fig. 7A and B, the PI3K-C2b overexpression plasmid signiﬁcantly
increased the PI3K-C2b protein level in SH-SY5Y cells compared
to the empty vector (pcDNA3) (P < 0.01). As shown in
Fig. 7C and D, transfection of PI3K-C2b expression plasmids
increased its protein levels, which were down-regulated by
miR-362-5p. A CCK-8 assay (Fig. 7E), and migration and invasion
assays (Fig. 7F and G) showed that overexpression of PI3K-C2b
Fig. 6. Inhibition of PI3K-C2b shows similar effects to miR-362-5p overexpression in SH-SY5Y cells. OD, optical density. (A) Protein level of PI3K-C2bwas detected byWestern
blot in SH-SY5Y cells transfected with PI3K-C2b or the negative control siRNA. (B) Intensity of PI3K-C2b protein in SH-SY5Y cells transfected with PI3K-C2b siRNA or negative
control siRNA (n = 5). (C) CCK-8 assay was used to determine the effect of PI3K-C2b siRNA on the proliferation of SH-SY5Y. Knockdown the expression of PI3K-C2b by siRNA
suppressed the (D) migration and (E) invasion of SH-SY5Y cells. *P < 0.05, **P < 0.01 compared with NC. NC, negative control siRNA.
K. Wu et al. / FEBS Letters 589 (2015) 1911–1919 1917could signiﬁcantly reverse the suppressive effect of miR-362-5p on
SH-SY5Y cells.
4. Discussion
In past decades, numerous genes were identiﬁed to relate with
neuroblastoma growth, invasion, and migration. miRNAs, which
are non-coding short-stranded RNAs, have been demonstrated to
play important roles in multiple aspects of tumor biology, such
as proliferation, invasion, and angiogenesis [16]. miRNAs have
been revealed as ‘onco(genic)-miRs’ or ‘tumor-suppressor miRs’
in neuroblastoma. Chen et al. reported that miR-338-3p suppresses
neuroblastoma proliferation, invasion and migration by targeting
PREX2a, which would affect the PTEN/Akt pathway [17]. Yang
et al. reported that miR-329 suppressed the growth and motility
of neuroblastoma by targeting KDM1A, which contributes to
tumorigenesis via activation of the Wnt/b-catenin signaling path-
way [8].
Many miRNAs are found to be up- or down-regulated in cancer
samples relative to their normal tissue counterparts, including
neuroblastoma. Human tissue miRNA microarray analysis showed
that numerous miRNAs are differentially expressed in high-risk
neuroblastoma compared with low-risk neuroblastoma. miR-30b,
miR-146a, miR-190, miR-204, miR-215, miR-299-5p, etc. [7,18]
were down-regulated in high-risk neuroblastoma. miR-362-5p
was also found to be aberrantly down-regulated in high-risk neu-
roblastoma tissues [7]. In this study, we conﬁrmed thatmiR-362-5p was down-regulated in metastatic neuroblastoma
(high-risk neuroblastoma) compared with primary neuroblastoma
(low-risk neuroblastoma) by qRT-PCR. Several mechanisms caused
miRNA dys-expression in cancer, such as Chromosomal abnormal-
ities [19], structural genetic alterations and Drosha or Dicer activ-
ity alterations. miRNA can also be affected by other miRNAs or
other mRNAs. Despite the advances in our understanding of the
mechanisms causing miRNA deregulation, the daunting task still
remains the elucidation of the biological role of miRNAs in the ini-
tiation and in the development of cancer.
miRNA play an important role in tumor biology. Xia et al.
reported that miR-362 induces cell proliferation and apoptosis
resistance in gastric cancer by activation of NF-jB signaling path-
way [13]. Fang et al. discovered that miR-362-5p was signiﬁcantly
up-regulated in hepatocellular carcinoma (HCC) and associated
with HCC progression. Inhibition of miR-362-5p in HCC cells dra-
matically decreased cell proliferation, clonogenicity, migration
and invasion in vitro as well as tumor growth and metastasis
in vivo by targeting the CYLD gene [20]. In our study, we demon-
strated that miR-362-5p decreased cell viability, proliferation,
migration, and invasion of neuroblastoma cells in vitro, and inhib-
ited tumor growth in a neuroblastoma nude mouse model in vivo.
The different roles of miRNA in cancers may mostly depend on the
roles of their target genes. Different cancer cells may have different
genetic backgrounds and miRNA expression proﬁles. There were
different gene phenotypes between neuroblastoma and HCC, and
miR-362-5p may play a different role by targeting different gene.
Fig. 7. PI3K-C2b overexpression reversed the suppressive effect of miR-362-5p in SH-SY5Y cells. OD, optical density. (A) Expression of PI3K-C2bwas detected by Western blot
in SH-SY5Y cells transfected with PI3K-C2b plasmid or pcDNA3 (the empty vector). (B) Intensity of PI3K-C2b protein in SH-SY5Y cells transfected with PI3K-C2b plasmid or
pcDNA3 (n = 5). (C–G) The SH-SY5Y cells were transfected with miR-362-5p plus pcDNA3, miR-362-5p plus PI3K-C2b expression plasmid or miR-NC plus pcDNA3. (C and D)
Protein level of PI3K-C2b was detected by Western blot (n = 5). The proliferation ability (E), migration (F) and invasion ability (G) were determined in SHSY5Y cells. *P < 0.05,
**P < 0.01 compared with miR-NC plus pcDNA3. #P < 0.05, ##P < 0.01 compared with miR-362-5p plus pcDNA3 group.
1918 K. Wu et al. / FEBS Letters 589 (2015) 1911–1919To date, the mechanism of the miR-362-5p function in
neuroblastoma has not been investigated. Several targets have
been identiﬁed by bioinformatics analysis. Here, we identiﬁed
PI3K-C2b as a novel target of miR-362-5p, and veriﬁed that
miR-362-5p decreased the PI3K-C2b protein level. PI3K generates
30-phosphorylated phosphoinositides as intracellular second
messengers and is a hallmark of many signaling pathways [21];
it controls multiple cellular responses, including proliferation,
growth and invasion. PI3K-C2b has also been reported to con-
tribute to the tumorigenesis of multiple cancers. Liu et al. reported
that PI3K-C2b is associated with oesophageal squamous cell
carcinoma metastasis and PI3K-C2b knockout enhanced
cisplatin-induced apoptosis, and inhibits metastasis of oesopha-
geal squamous cell carcinoma cells. Moreover, they demonstrated
that PI3K-C2b, via the Akt signaling pathway, might play a key role
in tumorigenesis [22]. PI3K-C2b has been identiﬁed as a potential
target for neuroblastoma tumor treatment [23]. Russo et al. discov-
ered that Intersectin 1-PI3K-C2b was an important pathway in
neuroblastoma tumorigenesis [24]. In this study, we also found
that inhibition of PI3K-C2b remarkably suppressed the growth
and motility of neuroblastoma cells, with similar effects to
miR-362-5p, while its overexpression successfully reversed the
effects of miR-362-5p. However, a miRNA may target many genes
and a single gene may be a target of many microRNA. Whetherother targets of miR-362-5p are involved in the regulation of neu-
roblastoma remains to be elucidated. Our results also showed that
miR-362-5p reduces the expression of PI3K-C2b to about 50% and
such small changes alone may not show any cellular phenotype.
However miR-362-5p has powerful cell inhibition function on neu-
roblastoma cells. It could be that miR-362-5p may target many
other genes in the same pathway or inﬂuence the other biological
processes or pathways.
In conclusion, we found that miR-362-5p can inhibit SH-SY5Y
cell proliferation, migration, and invasion in vitro and in
vivo. Our study identiﬁed a functional link between
miR-362-5p and PI3K-C2b expression in neuroblastoma, and also
demonstrated that PI3K-C2b was directly target of miR-362-5p.
miRNA may represent a promising treatment strategy for
neuroblastoma.
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